Lyrica approved for use in GAD

The licensed indications for Lyrica (pregabalin) have been extended to include the treatment of generalised anxiety disorder (GAD).

The recommended adult dose for use in the new indication is 150 to 600mg daily in two or three divided doses. The dose should be started at 150mg daily then, based on the patient's response, titrated in 150mg daily increments at weekly intervals to a maximum of 600mg daily.

Relief of symptoms may be expected within one week. The need for continued treatment should be reassessed regularly.

Lyrica is also indicated for use as adjunctive therapy in epilepsy for partial seizures with or without secondary generalisation and is available in seven different strengths: 25mg, 50mg, 75mg, 100mg, 150mg, 200mg and 300mg.

Further information: Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. Tel: (01304) 616161.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...